📰 Severe Plaque News
Severe Plaque News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Severe Plaque. Real-time updates on events, politics, business and more.
March 29, 2023
Tremfya demonstrated greater treatment persistence than interleukin-17 inhibitors in patients with moderate to severe plaque psoriasis and achieved clinical efficacy in scalp psoriasis, according to data presented here.Tremfya (guselkumab, Janssen Biotech) is the first and only fully human selective interleukin (IL)-23 approved in the United States for adults with moderate to severe plaque
January 12, 2023
- Seven posters will include clinical data for VTAMA cream for the treatment of plaque psoriasis in adults and atopic dermatitis (AD), including data from the successful pediatric maximum usage study
October 13, 2022
- Five posters will highlight clinical data for VTAMA cream for the treatment of plaque psoriasis in adults and for atopic dermatitis in patients as young as two - Dermavant Sciences, a biopharmaceutical
August 24, 2022
- Two posters will highlight clinical data for VTAMA cream on treat-to-target outcomes and quality of life measures - Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing
May 18, 2022
How Embark® App combines a medical and digital approach to support patients in managing their Enbrel® (etanercept) treatment.
April 19, 2022
Total sales growth of 5.0% to $23.4 Billion with operational growth of 7.7%* and adjusted operational growth of 7.9%* Earnings per share of $1.93 decreasing 16....
April 23, 2021
Share this article Share this article INDIANAPOLIS, April 23, 2021 /PRNewswire/ -- Through clinical trial meta-analysis and real-world evidence, Eli Lilly and Companys (NYSE: LLY) Taltz ® (ixekizumab) demonstrated greater success in key measured treatment outcomes compared to other biologics in adults with moderate to severe plaque psoriasis. In the first one-year network meta-analysis based on area under the curve, Taltz showed numerically greater cumulative benefits on completely clear skin...
February 19, 2021
Unichem Laboratories surged 5.71% to Rs 323.05 after the company received United States Food and Drug Administration (USFDA) approval for apremilast tablets, 10 mg, 20 mg and 30 mg. The drug is a generic version of Amgens Otezla (apremilast) tablets, 10 mg, 20 mg, and 30 mg. The drug is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. The scrip extended gains for third day. The stock has added 6.67% i...